Results 241 to 250 of about 132,229 (258)

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto

Annals of Oncology, 2018
Sherko Kuemmel, P Kläre, K E Weber
exaly  

Neoadjuvant Chemotherapy

2008
openaire   +1 more source

Neoadjuvant chemotherapy for operable breast cancer

British Journal of Surgery, 2007
Sven Mieog, J A van der Hage, C J H van de Velde   +2 more
exaly  

Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)†

Annals of Oncology, 2013
P Fasching, C Hanusch, Holger Eidtmann
exaly  

Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy

Annals of Oncology, 2015
Amna Sheri, Robin L Jones, Sarah E. Pinder   +2 more
exaly  

Neoadjuvant Chemotherapy

2011
openaire   +1 more source

PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer

Annals of Oncology, 2016
David Cunningham, Gina Brown, Josep Tabernero Caturla   +2 more
exaly  

OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer

Annals of Oncology, 2018
Charlie Gourley, I Romero, E A Eisenhauer   +2 more
exaly  

Neoadjuvant Chemotherapy

2010
openaire   +1 more source

Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy

Annals of Oncology, 2015
Emilia Montagna, Vincenzo Bagnardi, Marco Colleoni   +2 more
exaly